Abstract Antiphospholipid antibodies (aPLs) have been associated with recurrent thromboembolic events, thrombocytopenia, and cardiac valvular disease. Although these antibodies were originally described as a complication of systemic lupus erythematosus (SLE) and other connective tissue diseases, it is now recognized that aPLs can develop in the absence of other autoimmune disorders. Cross-sectional and prospective studies have suggested that aPLs are an independent risk factor for stroke, particularly when cerebral ischemia develops in young persons or in the setting of SLE. We will examine the present state of research on aPLs as a risk factor for thrombotic and embolic stroke and cerebral venous thrombosis. We will also review the current state of management strategies for patients with the antiphospholipid antibodies and stroke.